# Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer

> **NCT00253526** · PHASE2 · WITHDRAWN · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Adenocarcinoma of the Pancreas
- Recurrent Pancreatic Cancer
- Stage I Pancreatic Cancer
- Stage II Pancreatic Cancer
- Stage III Pancreatic Cancer

## Interventions

- **DRUG:** bevacizumab
- **DRUG:** gemcitabine hydrochloride
- **PROCEDURE:** adjuvant therapy
- **PROCEDURE:** anti-cytokine therapy
- **PROCEDURE:** antiangiogenesis therapy
- **PROCEDURE:** antibody therapy
- **PROCEDURE:** biological therapy
- **PROCEDURE:** chemotherapy
- **PROCEDURE:** conventional surgery
- **PROCEDURE:** growth factor antagonist therapy
- **PROCEDURE:** monoclonal antibody therapy
- **PROCEDURE:** surgery

## Key facts

- **NCT ID:** NCT00253526
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2015-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00253526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00253526, "Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT00253526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*